R(+) propranolol decreases lipid accumulation in haemangioma-derived stem cells
Infantile haemangioma (IH), often treated with propranolol, is a benign vascular tumour that undergoes a spontaneous involution to a fibrofatty residuum. We investigated how R(+) propranolol, the nonbeta blocker enantiomer of racaemic propranolol, affects lipid accumulation and adipogenesis in IH. This was motivated by our previous work showing that R(+) propranolol can block blood vessel formation in a preclinical model of IH. Our findings suggest a novel regulatory role for R(+) propranolol in modulating lipid accumulation in haemangioma stem cells. This highlights a novel role for R(+) propranolol in the involuting phase of IH and offers a strategy to reduce fibrofatty residua in IH.
Authors
- Mathias François (ORCID: https://orcid.org/0000-0002-9846-6882)
- J. Tan (ORCID: https://orcid.org/0009-0000-1901-7070)
- Annegret Holm (ORCID: https://orcid.org/0000-0002-8691-4131)
- Joyce Bischoff (ORCID: https://orcid.org/0000-0002-6367-1974)
- Jill Wylie‐Sears (ORCID: https://orcid.org/0000-0003-3305-8578)
- John B. Mulliken
- Caroline Theresa Seebauer (ORCID: https://orcid.org/0009-0002-2258-5604)
Institutions
- Boston Children's Hospital (US)
- The University of Sydney (AU)
- Harvard University (US)
- University of Lucerne (CH)
- Nanyang Technological University (SG)
- Centenary Institute (AU)
- University Hospital Regensburg (DE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1093/bjd/ljae452
- Citations
- 2
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Nanyang Technological University
- Deutsche Forschungsgemeinschaft
- University of Sydney
- National Institutes of Health
- Directorate for Biological Sciences
- Medical Research Council
- National Health and Medical Research Council
- National Heart, Lung, and Blood Institute